Duloxetine Versus Venlafaxine Extended Release in the Treatment of Major Depressive Disorder

The linear measure of global benefit-risk assessment. Benefit defined as remission at endpoint (HAMD 17 total score less than or equal to 7), a virtually symptom-free state.

HAMD17 Response Rates defined as greater than or equal to 50% reduction in HAMD17 total score from baseline to endpoint.

HAMD17 Time-to-First Response defined as the visit where a sustained greater than or equal to 30% reduction in the Maier subscale of the HAMD17.

HAMD17 Remission Rates defined as HAMD17 total score of less than or equal to 7 at endpoint.

Hamilton Anxiety Rating Scale measures the presence and severity of anxiety.

Clinical Global Impressions of Severity scale to record severity of illness at the time of assessment.

Patient's Global Impressions of Improvement scale measures improvement of the patient's symptoms.

HAMD17 Subscales evaluate severity of psychic and somatic manifestations of anxiety as well as agitation and evaluate dysfunction in mood, work, and sexual activity, as well as overall motor retardation and evaluate initial, middle, and late insomnia.